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Abstract
Background: Mesenchymal stromal cell (MSC)-based therapy is a promising strategy for preventing the progression
of chronic kidney disease (CKD), with the potential to induce tissue regeneration. In search of the best cellular source
we compared, in the rat model of adriamycin (ADR) nephropathy, the regenerative potential of human stromal cells of
non-renal origin, such as bone marrow (bm) MSCs and umbilical cord (uc) MSCs, with that of newly discovered stromal
cells of renal origin, the kidney perivascular cells (kPSCs) known to exhibit tissue-specific properties.
Methods: The therapeutic effect of repeated infusions of human bmMSCs, ucMSCs, kPSCs (1.5 × 106 cells/rats) or
conditioned medium from ucMSCs was studied in athymic rats with ADR-induced nephropathy (7.9 mg/kg). The ability
of the three stromal cell populations to engraft the damaged kidney was evaluated by detecting the presence of
human nuclear antigenpos cells. Glomerular podocyte loss and endothelial damage, sclerotic lesions and inflammation
were assessed at 14 and 28 days. In-vitro experiments with a transwell system were performed to investigate the
effects of different stromal cell populations on parietal epithelial cells (PECs) activated or not with albumin or
angiotensin II for 24 h.
Results: Infusions of non-renal and renal stromal cells resulted in a comparable engraftment into the kidney, in
the peritubular areas and around the glomerular structures. All three cell populations limited podocyte loss and
glomerular endothelial cell injury, and attenuated the formation of podocyte and PEC bridges. This translated into
a reduction of glomerulosclerosis and fibrosis. Human ucMSCs had an anti-inflammatory effect superior to that of
the other stromal cells, reducing macrophage infiltration and inducing polarisation towards the M2 macrophage
phenotype. Conditioned medium from ucMSCs shared the same renoprotective effects of the cells. Consistent
with in-vivo data, bmMSCs and kPSCs, but even more so ucMSCs, limited proliferation, migratory potential and
extracellular matrix production of activated PECs, when cultured in a transwell system.
Conclusions: Our data indicate that either non-renal or renal stromal cells induce renal tissue repair, highlighting
ucMSCs and their conditioned medium as the most reliable clinical therapeutic tool for CKD patients.
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Background
Chronic kidney disease (CKD) is a key factor in poor
health outcomes of major non-communicable diseases,
which are the leading cause of death worldwide. CKD oc-
curs in 10–11% of the adult population and can progress
towards end-stage renal disease (ESRD), a condition that
requires renal replacement therapy, such as kidney trans-
plantation or dialysis [1, 2]. Renal transplantation is lim-
ited by a shortage of organs, and in the next decade the
cost of dialysis will become unsustainable even in devel-
oped countries. Although considerable progress has been
made in delaying the onset of CKD through inhibition of
the renin–angiotensin system in a significant proportion
of patients, the search for new therapeutic approaches to
prevent or halt CKD progression remains a healthcare pri-
ority. In this context, cell-based therapy could be a prom-
ising strategy for treating CKD and is currently the focus
of preclinical studies. Initial findings highlighted the thera-
peutic potential of mesenchymal stromal cells (MSCs) of
bone marrow origin, in terms of their renotropism and re-
generative effects in experimental acute kidney injury
(AKI) [3–6]. Further studies demonstrated that the infu-
sion of human bone marrow (bm)-derived MSCs and,
even more, of human umbilical cord (uc) MSCs, amelio-
rated renal function and structure impairment, enhancing
tubular cell repair and survival in mice with AKI [7, 8].
The finding that both MSC populations engrafted the
renal tissue to a very low extent and did not incorporate
into tubular structures is fully consistent with their para-
crine activity to release spectra of prosurvival, anti-fibrotic
and anti-inflammatory biomolecules that accelerated the
process of renal repair in AKI [8, 9]. The evidence that
MSCs induced kidney regeneration via proliferation of en-
dogenous renal cells following injury suggested the intri-
guing possibility that the kidney might contain a
“renopoietic system” with progenitors capable of replacing
glomerular and tubular epithelial cells [10], opening new
avenues of investigation in regenerative medicine. In this
context, putative renal progenitor cells were isolated and
characterised, and when injected into animals with AKI
they were able to improve renal function and kidney tissue
integrity [11–13]. More recently, a new population of peri-
vascular stromal cells has been isolated from the human
kidney (kPSCs) [14]. This cell population shares strong
transcriptional similarities and common stromal cell
markers with human bmMSCs, although kPSCs show
renal tissue-specific expression signatures, including
HoxD10 and HoxD11 transcription factors, which are cru-
cial for nephrogenesis [14]. This tissue-specific imprinting
renders kPSCs functionally different and more effective
compared to bmMSCs, in terms of growth factor secre-
tion, renal integration and survival in the neonatal kidney,
and improvement of kidney injury when injected into
mice with glycerol-induced AKI [14].
Despite the proven therapeutic role of mesenchymal
stromal cells and renal progenitors in experimental AKI,
their efficacy in slowing the progression of CKD is, at the
very least, controversial [15, 16]. Preclinical studies dem-
onstrated that bmMSC-based therapy exerted protective
effects in limiting glomerular microvessel rarefaction, fi-
brosis and glomerulosclerosis, but failed to reduce pro-
teinuria in different models of CKD [17–19]. Interestingly,
human glomerular progenitor cells, which express mesen-
chymal stromal cell markers, integrated into glomerular
structures acquiring phenotypic features of podocytes, and
limited proteinuria and delayed progressive glomerular
sclerosis when infused in mice with adriamycin (ADR) ne-
phropathy [10]. Since none of the aforementioned studies
compared the therapeutic potential of stromal cell popula-
tions of non-renal and renal origin, here we investigated
the renoprotective effects of human bmMSCs or ucMSCs,
with respect to the renal stromal kPSCs in immunodefi-
cient rats with ADR-induced nephropathy. Furthermore,
we studied whether the potential “memory of origin” of
kPSCs could imply a higher capacity to integrate into the
kidney structures and to repair injured renal tissues
better than cells of non-renal origin, such as bmMSCs
or ucMSCs. Another important goal was to test and
compare the therapeutic efficacy of stromal cell-derived
conditioned medium with the effects of the corre-
sponding cell population.
Methods
Human cell isolation and characterisation
Human stromal cells of non-renal origin
Human bmMSCs and human ucMSCs were isolated and
characterised as previously described [20, 21]. Detailed
methods are provided in Additional file 1: Supplementary
Methods.
Human kidney perivascular stromal cells
Human kPSCs were isolated from human transplant-
grade kidneys, discarded for surgical reasons, by using
clinical-grade protocols, enzymes and products, as previ-
ously described [14]. Briefly, within 30 h after surgery,
the renal artery was cannulated and the kidney was per-
fused with collagenase and DNAse. After approximately
30 min, the tissue was digested and the cell suspension
was cultured and expanded in αMEM 1× Glutamax
(Thermo Fisher Scientific Life Science, Waltham, MA,
USA; http://www.thermofisher.com) containing 5%
platelet lysate, glutamine and penicillin/streptomycin. At
passage 1, the kPSC population was isolated using
MACS on the basis of NG2 expression [14]. Flow cyto-
metric analysis was used to analyse the kPSC phenotype.
In addition to NG2, kPSCs were positive for PDGF-R-β,
CD146, CD73, CD90 and CD105, while being negative
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for CD31, CD34, CD45 and CD56. Osteogenic and
chondrogenic, but not adipogenic, differentiation was
observed in kPSCs [14].
All of the populations of stromal cells of non-renal
and renal origin used for both in-vitro and in-vivo ex-
periments were used within the fourth to sixth passage.
To prepare conditioned medium (CM), ucMSCs were
incubated for 15 h in αMEM 1× Glutamax (Thermo
Fisher Scientific Life Science) in serum-free conditions.
Then, the medium was collected and centrifuged at 2000
× g for 20 min at 4 °C to remove cellular debris. After cen-
trifugation, supernatant was transferred into Amicon
Ultra-15 centrifugal Filter Devices with a 3000 molecular
weight cutoff (Merck Millipore, Darmstadt, Germany;
http://www.merckmillipore.com) and centrifuged at 4000
× g for 20 min to concentrate the volume of CM. Each ali-
quot of CM (500 μl) injected into ADR rats was obtained
from 1.5 × 106 ucMSCs.
Human parietal epithelial cells
Human parietal epithelial cells (PECs) were isolated and
characterised as previously described [22]. Detailed
methods are provided in Additional file 1: Supplemen-
tary Methods.
In-vitro co-culture experiments
PECs were seeded at a density of 20,000 cells/cm2 on
cover slips placed in the low chamber of a transwell
system (Sigma-Aldrich, St. Louis, MO, USA; https://
www.sigmaaldrich.com). One day later, the medium was
replaced with experimental medium alone containing
EBM (Lonza, Basel, Switzerland; http://www.lonza.com),
1% fetal bovine serum Hyclone (FBS HY; Thermo Fisher
Scientific Life Science) and 1% penicillin streptomycin
(PS; Thermo Fisher Scientific Life Science) with or with-
out Angiotensin II (Ang II; 10− 7 M; Sigma-Aldrich) or
human serum albumin (alb) (10 mg/ml; Sigma-Aldrich).
After 9 h, bmMSCs, ucMSCs or kPSCs were seeded on
0.4-μm inserts (Sigma-Aldrich) at a concentration of
20,000 cells/cm2 in order to maintain an equal propor-
tion with PECs. Empty inserts were also added to the
wells of control PECs, PECs + Ang II or PECs + albumin
to maintain the same conditions in all experimental groups.
After 15 h of co-culture, inserts were removed and PECs
were fixed with 2% paraformaldehyde (PFA) (Electron Mi-
croscopy Sciences, Hatfield, PA, USA; https://www.emsdia-
sum.com) + 4% sucrose (Sigma-Aldrich) and then used for
immunofluorescence studies as already described (see
Fig. 5a).
Rat model of ADR-induced nephropathy
Male athymic rats (Hsd: RH-Foxn1rnu; Envigo RMS Srl,
Udine, Italy; http://www.envigo.com), with initial body
weights of 200–250 g, were used for the experiments.
Animals were housed in a constant-temperature room
with a 12-h dark/12-h light cycle in a specific
pathogen-free facility, and fed a standard diet. Disease
was induced through a single infusion of adriamycin
(ADR, 7.9 mg/kg; Pfizer Italia s.r.l, Latina, Italy; http://
www.pfizer.it) in the rat tail vein. Thirty-six hours after
ADR treatment, rats were divided into five groups and
intravenously (i.v.) injected with saline (n = 14), human
bone marrow MSCs (1.5 × 106 cells/rat/infusion, n = 7),
human umbilical cord MSCs (1.5 × 106 cells/rat/infusion,
n = 13), human kidney perivascular stromal cells (1.5 × 106
cells/rat/infusion, n = 7) or CM obtained from ucMSCs
(CM derived from 1.5 × 106 cells/rat/infusion, n = 6). In-
jections of stromal cells were repeated at different times
as shown in Additional file 1: Figure S1a. Five normal rats,
i.v. injected with saline, served as controls. Twenty-four-
hour urine samples were collected using metabolic cages,
and proteinuria was measured using the Coomassie
method with a Cobas Mira autoanalyser (Roche Diagnos-
tics System, Basel, Switzerland; http://www.roche.com).
Renal function was assessed as blood urea nitrogen
(BUN), in serum samples at 28 days, using the Reflotron
test (Roche Diagnostics) according to the manufacturer’s
instructions. Rats were sacrificed at 14 or 28 days after
ADR injection, and the kidneys were removed for hist-
ology and immunohistochemistry analyses. Other organs
such as the heart, liver and lung were collected for immu-
nohistochemistry analyses. Detailed methods and a list of
antibodies used for human stromal cell engraftment, renal
morphology and immunohistochemistry are provided in
Additional file 1: Supplementary Methods.
Immunofluorescence studies in vitro
Detailed methods and a list of antibodies used to study
PEC activation are provided in Additional file 1:
Supplementary Methods.
Statistical analysis
Results are expressed as mean ± SE. Data were analysed
by ANOVA test coupled with Tukey or Dunnet post-hoc
analysis, as appropriate. The statistical significance level
was defined as p < 0.05. Data analysis was performed
using GraphPad Prism (GraphPad Prism Software, Inc.,
La Jolla, CA, USA; https://graphpad.com).
Results
In-vivo studies
Engraftment of non-renal and renal stromal cells into the
kidney of rats with ADR nephropathy
The efficacy of cell-based therapies with stromal cells of
non-renal and renal origin was investigated by comparing
the renoprotective effects of bmMSCs and ucMSCs with
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kPSCs in immunocompromised rats with ADR-induced
nephropathy, a model mimicking focal segmental glomer-
ulosclerosis [23]. At 7 days, athymic rats injected with
ADR exhibited proteinuria, which increased progressively
over time (Table 1). Proteinuria was associated with glom-
erular podocyte and endothelial cell damage and the for-
mation of synechiae, resulting in glomerulosclerotic
lesions at 28 days after ADR injection (Figs. 1, 2, and 3).
At this time, renal function, assessed as BUN, was within
the normal range (Additional file 1: Table S1) .
The ability of human bmMSCs or ucMSCs to migrate
into the damaged kidney was compared with that of
kPSCs, the stromal cell population that exhibits renal
tissue-specific imprinting [14]. Because of the severity of
the disease, ADR rats received six infusions of non-renal
or renal stromal cells in order to maintain, virtually, a con-
stant number of engrafted cells in the injured kidneys
throughout the course of the disease (Additional file 1:
Figure S1a). Quantification of the intra-renal recruitment
of human cells, positive for the human nuclear antigen
(HNA), in ADR rats at day 14 showed that bmMSCs
engrafting the kidney averaged 2.5 ± 0.4/105 renal cells,
ucMSCs averaged 3.1 ± 0.4/105 renal cells and kPSCs
averaged 3.2 ± 0.8/105 renal cells. Similar renal engraft-
ment was detected when human cells were labelled with
the anti-human mitochondria antibody (bmMSCs
3.7 ± 0.5/105 renal cells, ucMSCs 3.2 ± 1.1/105 renal
cells and kPSCs 2.6 ± 0.5/105 renal cells), thus indicat-
ing that all of the cell populations migrated into the
damaged renal tissue to a similar extent. Moreover,
non-renal as well as renal stromal cells predominantly
localised in the peritubular areas and around the glom-
erular structures (Additional file 1: Figure S1b). At
14 days, the analysis of other organs such as the heart
and liver showed the absence of human cell engraft-
ment in ADR rats infused with non-renal or renal
stromal cells. Conversely, rare single human stromal
cells were found in the lung parenchyma.
Effect of non-renal and renal stromal cells on glomerular
podocyte and endothelial cell injury
Since podocytes are one of the main targets of glomerular
injury in ADR nephropathy [18, 19], we evaluated the ef-
fects of injections of non-renal and renal stromal cells on
podocyte loss in ADR rats. Using morphometric analysis,
a significant reduction in the number of WT-1-positive
cells was observed in ADR rats receiving saline compared
to control rats at both 14 and 28 days (35% and 40% podo-
cyte reduction, respectively) (Fig. 1a–c). In the same ani-
mals, the expression of nephrin, a key protein of the slit
diaphragm, was reduced as evidenced by glomerular stain-
ing at 14 days (nephrin expression: ADR + saline 2.5 ±
0.5% vs control 14.9 ± 0.7% glomerular area; p < 0.001)
(Additional file 1: Figure S1c). Systemic delivery of
bmMSCs, ucMSCs or kPSCs in ADR rats limited podo-
cyte loss, as indicated by the significantly higher number
of podocytes per glomerulus compared to ADR rats re-
ceiving saline (Fig. 1a–c). Treatment with ucMSCs par-
tially restored nephrin expression, which was unaffected
by bmMSCs or kPSCs (nephrin expression: ADR +
ucMSCs 6.4 ± 0.6%, ADR + bmMSCs 2.6 ± 0.3% and ADR
+ kPSCs 4.3 ± 0.8% glomerular area) (Additional file 1: Fig-
ure S1c). Therapy with the three stromal cell populations
did not ameliorate proteinuria (Table 1) and renal func-
tion (Additional file 1: Table S1).
In parallel to podocyte injury, a marked glomerular
microvessel rarefaction, evaluated as the percentage of
endothelial cell volume density (%Vv), was observed in
ADR rats receiving saline at 14 and 28 days (Fig. 1d–f ).
Notably, at these time points, treatments with bmMSCs,
ucMSCs or kPSCs significantly limited glomerular endo-
thelial cell injury (Fig. 1d–f ).
Then, we analysed whether non-renal or renal stromal
cell therapies could limit glomerular podocyte and endo-
thelial cell injury in ADR rats by preventing cell apop-
tosis. ADR rats receiving saline exhibited an increased
number of glomerular apoptotic cells positive for cleaved
caspase-3 at 14 days (Additional file 1: Figure S2a, b).
Infusions of bmMSCs, ucMSCs or kPSCs significantly
decreased glomerular cell apoptosis (Additional file 1:
Figure S2a, b).
Effect of non-renal and renal stromal cells on renal fibrosis
In experimental ADR nephropathy, podocyte injury
promotes PEC activation and dysfunction, which leads
to the formation of synechiae and glomerulosclerotic
lesions [18, 22, 24–26]. In our setting, intercellular ad-
hesions between the glomerular tuft and the Bowman’s
capsule with a score of ≥ 3 were found in more than
Table 1 Time course of urinary protein excretion in control and
ADR rats receiving saline, bmMSCs, ucMSCs, kPSCs or CM-ucMSCs
Proteinuria (mg/day)
0 days 7 days 14 days 21 days 28 days
Control 6 ± 1.1 10 ± 1.3 12 ± 1.2 13 ± 1.3 13 ± 1.7
ADR + saline 7 ± 0.6 71 ± 7* 344 ± 29* 528 ± 26* 501 ± 53*
ADR + bmMSCs 7 ± 0.7 59 ± 12* 270 ± 19* 411 ± 17* 526 ± 36*
ADR + ucMSCs 7 ± 0.6 71 ± 11* 345 ± 16* 476 ± 15* 512 ± 43*
ADR + kPSCs 7 ± 0.4 63 ± 11* 355 ± 28* 471 ± 52* 486 ± 38*
ADR + CM-ucMSCs 8 ± 0.6 73 ± 13* 366 ± 40* 527 ± 37* 454 ± 48*
Data presented as mean ± standard error
ADR adriamycin, bmMSC bone marrow mesenchymal stromal cell, ucMSC umbilical
cord mesenchymal stromal cell, kPSC kidney perivascular stromal cell, CM-ucMSC
conditioned medium obtained from umbilical cord mesenchymal stromal cell
*p < 0.001 vs control at the corresponding time. Analysis of variance corrected
with Tukey coefficient
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Fig. 1 (See legend on next page.)
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Fig. 1 Human bmMSCs, ucMSCs, kPSCs or CM-ucMSCs reduce glomerular podocyte and endothelial cell injury in ADR rats. a, b Quantification of
podocyte number by morphometric analysis of WT1-positive podocytes in control and ADR rats receiving saline, bmMSCs, ucMSCs, kPSCs or CM-ucMSCs
at 14 days (a) and 28 days (b). Data are mean ± SE. ***p< 0.001 vs control; °p< 0.05 and °°p< 0.01 vs ADR + saline. c Representative micrographs of renal
sections from control and ADR rats receiving saline, bmMSCs, ucMSCs, kPSCs or CM-ucMSCs showing WT-1-positive podocytes (red) at 14 days. Scale bar
20 μm. d, e Quantification of capillary volume density (Vv) expressed as percentage of rat endothelial cell antigen-1 (RECA-1)-positive
glomerular endothelial cells in control and ADR rats receiving saline, bmMSCs, ucMSCs, kPSCs or CM-ucMSCs at 14 days (d) and 28 days (e). Data are
mean ± SE. **p < 0.01 and ***p < 0.001 vs control; °p < 0.05 and °°°p < 0.001 vs ADR + saline. f Representative images of glomerular endothelial cells
stained with RECA-1 in renal sections of control and ADR rats receiving saline, bmMSCs, ucMSCs, kPSCs or CM-ucMSCs at 14 days. Scale bar 20 μm.
ADR adriamycin, bmMSC bone marrow-derived mesenchymal stromal cell, CM-ucMSC conditioned medium obtained from umbilical cord-derived
mesenchymal stromal cell, DAPI 4′,6-diamidino-2-phenylindole, kPSC kidney perivascular stromal cell
Fig. 2 Treatment with human bmMSCs, ucMSCs, kPSCs or CM-ucMSCs reduces synechiae formation. a Percentage of glomeruli affected by different
degrees of synechiae (intercellular podocyte–PEC bridges) in control and ADR rats receiving saline, bmMSCs, ucMSCs, kPSCs or CM-ucMSCs at 14 days.
To evaluate synechiae formation, each glomerulus was assigned a score between 0 (no lesion) and 4; values expressed as mean percentage ± SE.
**p < 0.01 and ***p < 0.001 vs control; °p < 0.05, °°p < 0.01 and °°°p < 0.001 vs ADR + saline at the corresponding score. b Representative images of PECs
and podocytes stained with claudin 1 (red) and nestin (green), respectively, in renal sections of control and ADR rats receiving saline, bmMSCs, ucMSCs,
kPSCs or CM-ucMSCs at 14 days. Nuclei stained with DAPI (blue). Scale bar 20 μm. ADR adriamycin, bmMSC bone marrow-derived mesenchymal stromal
cell, CM-ucMSC conditioned medium obtained from umbilical cord-derived mesenchymal stromal cell, DAPI 4′,6-diamidino-2-phenylindole, kPSC kidney
perivascular stromal cell
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80% of glomeruli in ADR rats receiving saline at 14 days
(Fig. 2a). The phenotype of cells contributing to the for-
mation of synechiae was characterised by co-staining of
claudin 1 and nestin, specific markers of PECs and
podocytes, respectively. Immunofluorescence staining
revealed that both glomerular cell populations partici-
pated in the formation of synechiae. In particular, thick-
ening of the Bowman’s capsule was characterised by
multiple layers of claudin-1-positive cells, which mi-
grated towards the capillary tuft, creating cellular
bridges with podocytes in the renal tissue of ADR rats
at 14 days (Fig. 2b). Treatments with bmMSCs,
ucMSCs or kPSCs significantly lowered the percentage
of glomeruli affected by synechiae with a high score
compared to that observed in ADR rats given saline,
while the number of glomeruli with no or few adhe-
sions (score 0–2) increased (Fig. 2a), as also appeared
in the representative images of Fig. 2b.
Synechiae formation was followed by the develop-
ment of glomerular fibrotic and sclerotic lesions. As
shown in Fig. 3a, b, at 28 days we observed a significant
increase in fibronectin staining along the Bowman’s
capsule in the renal tissues of ADR-treated rats com-
pared to control rats. Infusions of ucMSCs or kPSCs,
but not of bmMSCs, markedly reduced fibronectin de-
position. Consistently, ADR-treated rats exhibited a sig-
nificant increase in the percentage of glomeruli filled by
sclerotic lesions at 28 days (Fig. 3c). Glomerulosclerotic
lesions were less diffuse and severe in the renal tissues
of ADR rats treated with ucMSCs or kPSCs (50% and
45% reduction, respectively) compared to rats receiving
saline (Fig. 3c). Since TGF-β is a potent promoter of
renal fibrotic processes and its upregulation is a com-
mon feature of many forms of CKD [27], we analysed
its concentration in serum samples from ADR rats. At
14 days, a marked increase in TGF-β serum levels was
observed in ADR rats given saline, compared to control
rats (control 78 ± 7 ng/ml vs ADR + saline 126 ± 9 ng/
ml; p < 0.01). At this time, injections of ucMSCs and
kPSCs, but not of bmMSCs, normalised serum TGF-β
Fig. 3 Effect of human bmMSC, ucMSC, kPSC or CM-ucMSC infusions on renal fibrosis and glomerulosclerosis. a Quantification of fibronectin
deposits along Bowman’s capsule in control and ADR rats receiving saline, bmMSCs, ucMSCs, kPSCs or CM-ucMSCs at 28 days. Score between 0
and 3 assigned by evaluating thickness of Bowman’s capsule. Data are mean ± SE. ***p < 0.001 vs control; °p < 0.05 and °°p < 0.01 vs ADR + saline.
b Representative images showing fibronectin expression in renal sections of control and ADR rats receiving saline, bmMSCs, ucMSCs, kPSCs or
CM-ucMSCs at 28 days. Scale bar 20 μm. c Quantification of glomeruli affected by sclerotic lesions (%GS) assessed in PAS-stained kidney sections
of control and ADR rats receiving saline, bmMSCs, ucMSCs, kPSCs or CM-ucMSCs at 28 days. Data are mean ± SE. ***p < 0.001 vs control. ADR
adriamycin, bmMSC bone marrow-derived mesenchymal stromal cell, CM-ucMSC conditioned medium obtained from umbilical cord-derived
mesenchymal stromal cell, kPSC kidney perivascular stromal cell
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(ADR+ bmMSCs 145 ± 9 ng/ml, ADR + ucMSCs 93 ± 10
ng/ml and ADR+ kPSCs 86 ± 10 ng/ml; p < 0.05).
Effect of non-renal and renal stromal cells on monocyte/
macrophage infiltration in the kidney
We then explored the anti-inflammatory activity of
bmMSCs and ucMSCs versus kPSCs in ADR nephropa-
thy. A large number of ED1-positive monocytes/macro-
phages accumulated in the renal tissues of ADR rats given
vehicle at 14 days (Fig. 4a). Treatment with non-renal and
renal stromal cell populations had a remarkable
anti-inflammatory effect, resulting in a significant
reduction in the number of infiltrating monocytes/macro-
phages (Fig. 4a, c). Since bmMSCs are known to be able
to promote the shift of macrophages from the proinflam-
matory M1 to the anti-inflammatory M2-like phenotype
[28], we studied whether therapies with the three stromal
cell populations could modulate macrophage phenotypic
changes in the setting of ADR nephropathy. Co-staining
of ED1-positive monocytes/macrophages with CD206, a
marker highly expressed by M2 macrophages [29], re-
vealed a significant decrease in the percentage of M2 mac-
rophages over the totality of ED1-positive cells (Fig. 4b, c).
Notably, treatment with the three stromal cell populations
Fig. 4 Human bmMSCs, ucMSCs, kPSCs or CM-ucMSCs decrease renal macrophage infiltration. a Quantification of ED1-positive monocytes/macrophages
per field in renal tissue of control and ADR rats receiving saline, bmMSCs, ucMSCs, kPSCs or CM-ucMSCs at 14 days. Data are mean ± SE. ***p< 0.001 vs
control; °°p< 0.01 vs ADR+ saline. b Quantification of macrophages with anti-inflammatory M2 phenotype expressed as percentage of CD206-positive
macrophages per total ED1-positive cells in renal sections of control and ADR rats receiving saline, bmMSCs, ucMSCs, kPSCs or CM-ucMSCs at 14 days.
Data are mean ± SE. ***p< 0.001 vs control; °°°p< 0.001 vs ADR + saline; ###p< 0.001 vs ADR+ saline + bmMSCs or kPSCs. c Representative images of
ED1-positive monocytes/macrophages (green) and anti-inflammatory M2 macrophages labelled with CD206 (red) in renal tissue of control and ADR rats
receiving saline, bmMSCs, ucMSCs, kPSCs or CM-ucMSCs at 14 days. Nuclei stained with DAPI (blue). Scale bar 20 μm. ADR adriamycin, bmMSC bone
marrow-derived mesenchymal stromal cell, CM-ucMSC conditioned medium obtained from umbilical cord-derived mesenchymal stromal cell, DAPI
4′,6-diamidino-2-phenylindole, kPSC kidney perivascular stromal cell
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enhanced the percentage of M2 macrophages. In particu-
lar, ucMSCs exhibited the most potent anti-inflammatory
properties (Fig. 4b, c).
Treatment with ucMSC-derived conditioned medium is
renoprotective in rats with ADR nephropathy
Since ucMSCs appeared to be the most effective cells that
exert paracrine activity on renal cells, we tested whether
their conditioned medium (CM) had a therapeutic effect
similar to that observed with the corresponding cells.
Repeated injections of CM-ucMSCs preserved podocyte
loss, compared to ADR rats treated with saline (Fig. 1a–c).
No changes in nephrin expression (day 14: ADR +
CM-ucMSCs 2.0 ± 0.5% vs ADR + saline 2.5 ± 0.5% glom-
erular area) (Additional file 1: Figure S1c) and proteinuria
(Table 1) were observed. Treatment with CM significantly
limited glomerular microvessel rarefaction by restoring
endothelial cell volume density at both 14 and 28 days
(Fig. 1d–f ). Moreover, ADR rats infused with CM showed
a remarkable decrease in glomerular apoptotic cells posi-
tive for cleaved caspase-3 at 14 days (Additional file 1:
Figure S2a, b).
When we looked at synechiae formation, we observed
that the percentage of damaged glomeruli with a high
score (score 4) was significantly lower in CM-treated
ADR rats, which exhibited a normal glomerular podo-
cyte and PEC distribution (Fig. 2a, b). In addition, re-
duced fibronectin deposition along the Bowman’s
capsule and decreased glomerulosclerosis were consist-
ently observed in ADR rats in response to CM therapy
(Fig. 3a–c). The beneficial effect of CM on fibrotic le-
sions was associated with the reduced serum levels of
TGF-β at 14 days (ADR + CM-ucMSCs 83 ± 4 ng/ml vs
ADR + saline 126 ± 9 ng/ml; p < 0.01). CM had a signifi-
cant anti-inflammatory effect, as demonstrated by a
lower number of infiltrated ED1 macrophages and a sig-
nificant increase of M2 macrophages in the renal tissues
of ADR rats (Fig. 4a–c). These data indicate that treat-
ment with conditioned medium shared the renoprotec-
tive effects observed with ucMSC therapy.
In-vitro studies
To identify the molecular processes driving the recovery
of the PEC phenotype in vivo in response to cell therap-
ies, in-vitro experiments were performed using a trans-
well system. PECs were activated Ang II or albumin,
mimicking the disease condition, and were co-cultured
with bmMSCs, ucMSCs or kPSCs seeded on the insert
of the transwell (Fig. 5a). PEC proliferation was studied
by evaluating the number of cell nuclei positive for
phospho H3-histone (P-H3), a marker of mitosis. Results
showed that PECs exposed for 24 h to Ang II or albumin
proliferated markedly compared to control cells (Fig. 5b,
c). Co-culture of activated PECs with bmMSCs, ucMSCs
or kPSCs significantly decreased PEC proliferation in re-
sponse to both stimuli. Notably, ucMSCs inhibited PEC
proliferation to a more significant extent than bmMSCs
or kPSCs did (Fig. 5b, c). To further investigate the
mechanisms regulating PEC proliferation, we studied the
expression of sestrin 2 (Sesn2), a stress-inducible protein
that counteracts oxidative stress and represses cell pro-
liferation by targeting mTOR signalling [30, 31]. As
shown in Fig. 5d, e, control PECs constitutively
expressed Sesn2, which decreased markedly following
Ang II and albumin exposure. Transwell co-culture of
bmMSCs, ucMSCs or kPSCs significantly upregulated
Sesn2 expression in PECs activated with both stimuli
(Fig. 5d, e).
Several pieces of in-vivo evidence demonstrated that
activated PECs, migrating towards the glomerular capil-
lary tuft, are important players in the development and
progression of glomerular damage [22]. Since PEC mi-
gration involves the loss of cell–cell interaction along
the Bowman’s capsule, we evaluated the expression of
claudin 1, a tight junction protein that is constitutively
expressed by PECs. Parietal epithelial cells activated by
Ang II showed a significant decrease in claudin 1 expres-
sion, compared to control cells, that was restored when
PECs were in co-culture with bmMSCs or ucMSCs, but
not kPSCs (Fig. 6a). Notably, ucMSCs increased claudin
1 expression more efficiently in activated PECs (Fig. 6a).
Similar data were obtained when PECs activated with al-
bumin were co-cultured with stromal cells (Fig. 6b).
Next, the capacity of stromal cells to modulate
extracellular matrix (ECM) production by activated
PECs was explored. Both Ang II and albumin enhanced
the production of fibronectin compared to control PECs
(Fig. 6c, d), which was significantly reduced by
co-culture with bmMSCs, ucMSCs or kPSCs (Fig. 6c, d).
These in-vitro data demonstrate that the human stromal
cells of non-renal and renal origin are likewise able to
limit PEC dysfunction, restoring their phenotype, and
propose ucMSCs as the most effective cell population.
Discussion
This study provides novel insights into the therapeutic
potential of human stromal cells of different origins,
having compared the regenerative activity of non-renal
and renal stromal cells in a chronic model of adriamycin
(ADR)-induced nephropathy. In this setting, we also
provide the proof of concept that therapy with stromal
cell-derived conditioned medium mimics the renopro-
tective effects of the corresponding cells.
Our results demonstrate that all of the stromal cell
populations tested—bmMSCs, ucMSCs or kPSCs—were
able to promote renal repair by limiting podocyte loss
and glomerular capillary rarefaction, ultimately leading
to a reduction in PEC dysfunction. It is well established
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Fig. 5 (See legend on next page.)
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that podocyte injury is one of the first events to trigger
the aberrant activation of PECs [18, 22, 32, 33] which,
after losing cell–cell contact, begin to proliferate and mi-
grate, leading to hyperplastic-like lesions, a detrimental
step that drives the formation of fibrosis and glomerulo-
sclerosis. The present data, showing that non-renal or
renal stromal cells inhibit the production of profibrotic
factors and minimise glomerular fibrosis and, to a lesser
extent sclerotic lesions, point to dysfunctional podocytes
and PECs as valuable targets for cell-based therapies,
which can restore the structural integrity of glomeruli.
The fact that none of the cell treatments affect protein-
uria could be ascribed to the partial recovery of the
podocyte slit diaphragm proteins, which are not suffi-
cient to restore normal structure of the foot processes,
as also previously described [18, 19].
Seeking to identify the mechanisms that may sustain
the process of renal repair, we focused on the effects of
stromal cell therapies on inflammatory cell infiltration
[34], a typical feature of progressive CKD [35, 36].
Converging evidence demonstrates that macrophages play
a key role in host defence and homeostatic functions, in-
cluding tissue repair and the regulation of metabolic activ-
ities [37]. Depending on the local microenvironment,
macrophages can acquire two opposing and competing
functional phenotypes, often referred to as classical acti-
vated M1 macrophages, with proinflammatory activity,
and M2 macrophages, which have anti-inflammatory and
tissue repair functions, due to their peculiar secretion pro-
file [35]. The effects of MSCs on macrophage polarisation,
and their potential to alter the proinflammatory course of
renal disease, remain largely unknown. Our study demon-
strates that the accumulation of proinflammatory macro-
phages in damaged kidneys is reduced by cell treatments,
documenting that either non-renal or renal stromal cells
have strong anti-inflammatory activity. The picture that
emerges, accompanied by evidence that M1 macrophages
switch towards the M2 phenotype, suggests that cell ther-
apies counteract renal disease outcomes by regulating
macrophage polarisation, possibly through paracrine activ-
ity. These findings are consistent with previous studies,
which demonstrated the capacity of bmMSCs to drive
macrophage polarisation towards the M2 phenotype by
producing soluble factors, including PGE2, TSG6, IL-6,
IL-8, IDO and TGF-β1, following ischaemia reperfusion
injury, sepsis and other disease models in which inflam-
mation was the underlying mechanism [28, 38]. Notably,
ucMSCs and their conditioned medium have stronger
anti-inflammatory and renoprotective effects than the
other cell populations tested, which is probably ascrib-
able to a peculiar secretome profile of ucMSCs [39–41],
rather than their distinct ability to migrate into the in-
jured renal tissue. In this context, the finding that
kPSCs exhibit a capacity to engraft into the damaged
kidney that is similar to bmMSCs and ucMSCs, and
that they fail to incorporate into renal structures con-
trary to expectation, considering that the renal micro-
environment is their natural niche [14], may suggest
that renal stromal cells are renoprotective through a
paracrine activity like non-renal stromal cells are.
As well as producing pro-survival, anti-fibrotic and
anti-inflammatory soluble factors, stromal cells can also
release extracellular vesicles (EVs) which, by shuttling gen-
etic information such as mRNAs and transcriptional regu-
lators into target cells through specific receptor ligands,
can induce cell phenotypic changes and tissue repair [42,
43]. These mechanisms of MSC–cell interaction create
novel possibilities for the clinical application of stromal
cell therapy in regenerative medicine, because they bypass
the safety concerns and limitations associated with viable
cell transplantation [44]. In our CKD setting, the renopro-
tective effects of conditioned medium, possibly ascribable
to the presence of bioactive molecules and EVs, were con-
sistent with the evidence describing the regenerative ef-
fects of MSC-derived EV treatment for acute and chronic
renal diseases [45, 46].
It is possible to infer, as observed in vivo, that
non-renal and renal stromal cells, when in a co-culture
system, can communicate with glomerular cell popula-
tions through the release of soluble factors and EVs in
their conditioned media, thus reducing podocyte injury
[18] and PEC activation.
Indeed, bmMSCs and kPSCs, and particularly
ucMSCs, can produce factors able to limit the prolifera-
tion of activated PECs, possibly by normalising the ex-
pression of Sestrin 2, an inhibitor of mTOR mitogenic
(See figure on previous page.)
Fig. 5 Effect of human bmMSCs, ucMSCs or kPSCs on proliferation of activated PECs in co-culture system. a Schematic representation of experimental
design with activated human PECs and stromal cells in co-culture using a transwell system. b, c Representative images and quantification of proliferating
PECs positive for phospho H3-histone (P-H3) exposed to medium alone and angiotensin II (Ang II, 10− 7 M) (b) or albumin (alb, 10 mg/ml) (c)
and co-cultured with bmMSCs, ucMSCs or kPSCs. PEC nuclei stained with DAPI. Data expressed as percentage of P-H3 positive PECs per total
DAPI-positive cells/HPF. ***p < 0.001 vs PECs; °p < 0.05, °°p < 0.01 vs PECs + albumin; °°°p < 0.001 vs PECs + Ang II or albumin; ###p < 0.001 vs
PECs + Ang II + kPSCs. d, e Representative images and quantification of Sestrin 2 (Sesn2) expression in PECs exposed to medium alone and
Ang II (d) or alb (e) and co-cultured with bmMSCs, ucMSCs or kPSCs. PEC nuclei stained with DAPI (blue). Data expressed as MFI/cell. ***p < 0.001 vs
PECs; °p < 0.05 vs PECs + Ang II; °°p < 0.01 vs PECs + Ang II or alb; °°°p < 0.001 vs PECs + alb; ##p < 0.01 vs PECs + alb + kPSCs. Data are mean ± SE.
Scale bar 20 μm. bmMSC bone marrow-derived mesenchymal stromal cell, DAPI 4′,6-diamidino-2-phenylindole, HPF high-power field, kPSC kidney
perivascular stromal cell, MFI mean fluorescence intensity, PEC parietal epithelial cell, ucMSC umbilical cord-derived mesenchymal stromal cell
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signalling [31]. A previous study, which demonstrates
that the decrease in Sestrin 2 expression and consequent
mTOR activation in PECs is strongly associated with the
development of glomerular hyperplastic-like lesions and
periglomerular fibrosis in animal models of puromycin
nephropathy and crescentic glomerulonephritis, sup-
ports the idea that Sestrin 2 has a critical role in regulat-
ing the PEC phenotype [31]. Interestingly, our data
further show that exposing cultured activated PECs to
media conditioned by non-renal and renal stromal cells
Fig. 6 Effect of human bmMSCs, ucMSCs or kPSCs on claudin 1 and fibronectin expression in activated PECs. a, b Representative images and
quantification of claudin 1 expression in PECs exposed to medium alone and angiotensin II (Ang II) (a) or albumin (alb) (b) and co-cultured with
bmMSCs, ucMSCs or kPSCs. PEC nuclei stained with DAPI (blue). Data expressed as MFI/cell. **p < 0.01 and ***p < 0.001 vs PECs; °°p < 0.01 and
°°°p < 0.001 vs PECs + Ang II or alb; #p < 0.05 vs PECs + alb + kPSCs; ###p < 0.001 vs PECs + Ang II + kPSCs. c, d Representative images and
quantification of fibronectin (red) production by PECs exposed to medium alone and Ang II (c) or alb (d) and co-cultured with bmMSCs, ucMSCs
or kPSCs for 24 h. PEC nuclei stained with DAPI (blue). Data expressed as MFI/cell. ***p < 0.001 vs PECs; °p < 0.05 vs PECs + alb; °°°p < 0.001 vs
PECs + Ang II or alb. Data are mean ± SE. Scale bar 20 μm. bmMSC bone marrow-derived mesenchymal stromal cell, DAPI 4′,6-diamidino-2-
phenylindole, kPSC kidney perivascular stromal cell, MFI mean fluorescence intensity, PEC parietal epithelial cell, ucMSC umbilical cord-derived
mesenchymal stromal cell
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restores the abnormal extracellular matrix production
and the expression of claudin 1, a junctional protein
regulating their migratory behaviour. These data high-
light the potential of stromal cell-derived bioactive prod-
ucts, particularly those of ucMSCs, to counteract the
mitogenic and profibrotic activities of PECs during renal
disease.
Conclusion
These findings advance our knowledge of the therapeutic
potential of distinct stromal cell populations of non-renal
and renal origin in experimental progressive nephropathy,
pointing to human ucMSCs as the most attractive candi-
date for promoting renal tissue repair, possibly through
the preservation of glomerular structural and functional
integrity and by shutting down inflammatory processes.
Our data also demonstrate the renoprotective effects of
ucMSC-derived conditioned medium, which might be a
promising clinical therapeutic tool, overcoming the weak-
nesses and risks associated with the use of native stromal
cells for patients with CKD.
Additional file
Additional file 1: Supplementary Methods, Table and Figures.
(PDF 4792 kb)
Abbreviations
ADR: Adriamycin; AKI: Acute kidney injury; Ang II: Angiotensin II; bmMSC: Bone
marrow-derived mesenchymal stromal cell; BUN: Blood urea nitrogen;
CKD: Chronic kidney disease; CM: Conditioned medium; EV: Extracellular vesicle;
HNA: Human nuclear antigen; kPSC: Kidney perivascular stromal cell;
MSC: Mesenchymal stromal cell; mTOR: Mammalian target of rapamycin;
PEC: Parietal epithelial cell; P-H3: Phospho H3-histone; Sesn2: Sestrin 2;
TGF-β: Transforming growth factor beta; ucMSC: Umbilical cord-derived
mesenchymal stromal cell
Acknowledgements
The authors thank Monica Locatelli for renal histology assessment and
immunofluorescence experiment assistance, and Cristina Zanchi for support
in real-time PCR experiments. They also thank Manuela Passera for helping to
prepare the manuscript and Kerstin Mierke for editing the manuscript. CR is
recipient of a fellowship from Fondazione Aiuti per la Ricerca sulle Malattie
Rare (ARMR), Bergamo, Italy. DCe is recipient of a fellowship from Fondazione
Istituti Educativi di Bergamo, Bergamo, Italy.
Funding
This work was partially supported by funding from the European Union’s Seventh
Framework program, the STELLAR project (HEALTHF4–2012-305436).
Availability of data and materials
The data that support the findings of this study are available from the
corresponding author upon reasonable request.
Authors’ contributions
CR and MM contributed to conception and design of the study, collection
and/or assembly of data, data analysis and interpretation, and manuscript
writing. DCe, OC, DCo and DR contributed to collection and/or assembly of
data. MI and TJR contributed to provision of study material and final approval
of the manuscript. CC and DGL contributed to provision of study material. AB,
CZ and GR contributed to data analysis and interpretation, manuscript writing
and final approval of the manuscript. All authors read and approved the final
version of the manuscript.
Ethics approval and consent to participate
All procedures involving animals were performed in accordance with institutional
guidelines in compliance with national (D.L.n.26, 4 March 2014) and international
(directive 2010/63/EU on the protection of animals used for scientific purposes)
laws and policies, and were approved by the Institutional Animal Care and Use
Committees of Mario Negri Institute.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro Anna Maria
Astori, Science and Technology Park Kilometro Rosso, Via Stezzano 87, 24126
Bergamo, Italy. 2Laboratory of Cell Therapy “G. Lanzani”, Azienda Socio
Sanitaria Territoriale (ASST) Papa Giovanni XXIII, Bergamo, Italy. 3Department
of Internal Medicine, Leiden University Medical Centre, Leiden, The
Netherlands. 4Unit of Nephrology and Dialysis, Azienda Socio Sanitaria
Territoriale (ASST) Papa Giovanni XXIII, Bergamo, Italy. 5“L. Sacco” Department
of Biomedical and Clinical Science, University of Milan, Milan, Italy.
Received: 13 June 2018 Revised: 20 July 2018
Accepted: 24 July 2018
References
1. Perico N, Remuzzi G. Chronic kidney disease: a research and public health
priority. Nephrol Dial Transplant. 2012;27(Suppl 3):iii19–26.
2. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic
kidney disease: global dimension and perspectives. Lancet. 2013;382:260–72.
3. Morigi M, Imberti B, Zoja C, Corna D, Tomasoni S, Abbate M, et al.
Mesenchymal stem cells are renotropic, helping to repair the kidney and
improve function in acute renal failure. J Am Soc Nephrol. 2004;15:1794–804.
4. Herrera MB, Bussolati B, Bruno S, Fonsato V, Romanazzi GM, Camussi G.
Mesenchymal stem cells contribute to the renal repair of acute tubular
epithelial injury. Int J Mol Med. 2004;14:1035–41.
5. Tögel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C. Administered
mesenchymal stem cells protect against ischemic acute renal failure
through differentiation-independent mechanisms. Am J Physiol Renal
Physiol. 2005;289:F31–42.
6. Andrade L, Rodrigues CE, Gomes SA, Noronha IL. Acute kidney injury as a
condition of renal senescence. Cell Transplant. 2018;27:739-53.
7. Morigi M, Introna M, Imberti B, Corna D, Abbate M, Rota C, et al. Human
bone marrow mesenchymal stem cells accelerate recovery of acute renal
injury and prolong survival in mice. Stem Cells. 2008;26:2075–82.
8. Morigi M, Rota C, Montemurro T, Montelatici E, Lo Cicero V, Imberti B, et al.
Life-sparing effect of human cord blood-mesenchymal stem cells in
experimental acute kidney injury. Stem Cells. 2010;28:513–22.
9. Perico L, Morigi M, Rota C, Breno M, Mele C, Noris M, et al. Human
mesenchymal stromal cells transplanted into mice stimulate renal tubular
cells and enhance mitochondrial function. Nat Commun. 2017;8:983.
10. Ronconi E, Sagrinati C, Angelotti ML, Lazzeri E, Mazzinghi B, Ballerini L, et al.
Regeneration of glomerular podocytes by human renal progenitors. J Am
Soc Nephrol. 2009;20:322–32.
11. Oliver JA, Maarouf O, Cheema FH, Martens TP, Al-Awqati Q. The renal papilla
is a niche for adult kidney stem cells. J Clin Invest. 2004;114:795–804.
12. Bussolati B, Bruno S, Grange C, Buttiglieri S, Deregibus MC, Cantino D, et al.
Isolation of renal progenitor cells from adult human kidney. Am J Pathol.
2005;166:545–55.
13. Sagrinati C, Netti GS, Mazzinghi B, Lazzeri E, Liotta F, Frosali F, et al. Isolation
and characterization of multipotent progenitor cells from the Bowman’s
capsule of adult human kidneys. J Am Soc Nephrol. 2006;17:2443–56.
14. Leuning DG, Reinders MEJ, Li J, Peired AJ, Lievers E, de Boer HC, et al.
Clinical-grade isolated human kidney perivascular stromal cells as an
organotypic cell source for kidney regenerative medicine. Stem Cells Transl
Med. 2017;6:405–18.
Rota et al. Stem Cell Research & Therapy  (2018) 9:220 Page 13 of 14
15. Papazova DA, Oosterhuis NR, Gremmels H, van Koppen A, Joles JA, Verhaar
MC. Cell-based therapies for experimental chronic kidney disease: a
systematic review and meta-analysis. Dis Model Mech. 2015;8:281–93.
16. Hickson LJ, Eirin A, Lerman LO. Challenges and opportunities for stem cell
therapy in patients with chronic kidney disease. Kidney Int. 2016;89:767–78.
17. Ninichuk V, Gross O, Segerer S, Hoffmann R, Radomska E, Buchstaller A, et al.
Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not
delay progression of chronic kidney disease in collagen4A3-deficient mice.
Kidney Int. 2006;70:121–9.
18. Zoja C, Garcia PB, Rota C, Conti S, Gagliardini E, Corna D, et al. Mesenchymal
stem cell therapy promotes renal repair by limiting glomerular podocyte
and progenitor cell dysfunction in adriamycin-induced nephropathy. Am J
Physiol Renal Physiol. 2012;303:F1370–81.
19. Magnasco A, Corselli M, Bertelli R, Ibatici A, Peresi M, Gaggero G, et al.
Mesenchymal stem cells protective effect in adriamycin model of
nephropathy. Cell Transplant. 2008;17:1157–67.
20. Capelli C, Domenghini M, Borleri G, Bellavita P, Poma R, Carobbio A, et al.
Human platelet lysate allows expansion and clinical grade production of
mesenchymal stromal cells from small samples of bone marrow aspirates or
marrow filter washouts. Bone Marrow Transplant. 2007;40:785–91.
21. Capelli C, Gotti E, Morigi M, Rota C, Weng L, Dazzi F, et al. Minimally
manipulated whole human umbilical cord is a rich source of clinical-grade
human mesenchymal stromal cells expanded in human platelet lysate.
Cytotherapy. 2011;13:786–801.
22. Morigi M, Locatelli M, Rota C, Buelli S, Corna D, Rizzo P, et al. A previously
unrecognized role of C3a in proteinuric progressive nephropathy. Sci Rep.
2016;6:28445.
23. Bertani T, Poggi A, Pozzoni R, Delaini F, Sacchi G, Thoua Y, et al. Adriamycin-
induced nephrotic syndrome in rats: sequence of pathologic events. Lab
Investig J Tech Methods Pathol. 1982;46:16–23.
24. Benigni A, Morigi M, Rizzo P, Gagliardini E, Rota C, Abbate M, et al.
Inhibiting angiotensin-converting enzyme promotes renal repair by limiting
progenitor cell proliferation and restoring the glomerular architecture. Am J
Pathol. 2011;179:628–38.
25. Shankland SJ, Smeets B, Pippin JW, Moeller MJ. The emergence of the
glomerular parietal epithelial cell. Nat Rev Nephrol. 2014;10:158–73.
26. Smeets B, Kuppe C, Sicking E-M, Fuss A, Jirak P, van Kuppevelt TH, et al.
Parietal epithelial cells participate in the formation of sclerotic lesions in
focal segmental glomerulosclerosis. J Am Soc Nephrol. 2011;22:1262–74.
27. Loeffler I, Wolf G. Transforming growth factor-β and the progression of
renal disease. Nephrol Dial Transplant. 2014;29(Suppl 1):i37–45.
28. Zheng G, Ge M, Qiu G, Shu Q, Xu J. Mesenchymal stromal cells affect disease
outcomes via macrophage polarization. Stem Cells Int. 2015;2015:989473.
29. Geng Y, Zhang L, Fu B, Zhang J, Hong Q, Hu J, et al. Mesenchymal stem
cells ameliorate rhabdomyolysis-induced acute kidney injury via the
activation of M2 macrophages. Stem Cell Res Ther. 2014;5:80.
30. Budanov AV, Karin M. p53 target genes sestrin1 and sestrin2 connect
genotoxic stress and mTOR signaling. Cell. 2008;134:451–60.
31. Hamatani H, Hiromura K, Sakairi T, Takahashi S, Watanabe M, Maeshima A, et al.
Expression of a novel stress-inducible protein, sestrin 2, in rat glomerular
parietal epithelial cells. Am J Physiol Renal Physiol. 2014;307:F708–17.
32. Smeets B, Angelotti ML, Rizzo P, Dijkman H, Lazzeri E, Mooren F, et al. Renal
progenitor cells contribute to hyperplastic lesions of podocytopathies and
crescentic glomerulonephritis. J Am Soc Nephrol. 2009;20:2593–603.
33. Lasagni L, Ballerini L, Angelotti ML, Parente E, Sagrinati C, Mazzinghi B, et al.
Notch activation differentially regulates renal progenitors proliferation and
differentiation toward the podocyte lineage in glomerular disorders. Stem
Cells. 2010;28:1674–85.
34. Anders H-J, Ryu M. Renal microenvironments and macrophage phenotypes
determine progression or resolution of renal inflammation and fibrosis.
Kidney Int. 2011;80:915–25.
35. Meng X-M, Tang PM-K, Li J, Lan HY. Macrophage phenotype in kidney injury
and repair. Kidney Dis. 2015;1:138–46.
36. Cao Q, Harris DCH, Wang Y. Macrophages in kidney injury, inflammation,
and fibrosis. Physiol. 2015;30:183–94.
37. Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity
and polarization in tissue repair and remodelling. J Pathol. 2013;229:176–85.
38. Wise AF, Williams TM, Kiewiet MBG, Payne NL, Siatskas C, Samuel CS, et al.
Human mesenchymal stem cells alter macrophage phenotype and promote
regeneration via homing to the kidney following ischemia-reperfusion
injury. Am J Physiol Renal Physiol. 2014;306:F1222–35.
39. Donders R, Bogie JFJ, Ravanidis S, Gervois P, Vanheusden M, Marée R, et al.
Human Wharton’s jelly-derived stem cells display a distinct
immunomodulatory and proregenerative transcriptional signature compared
to bone marrow-derived stem cells. Stem Cells Dev. 2018;27:65–84.
40. Bai L, Li D, Li J, Luo Z, Yu S, Cao S, et al. Bioactive molecules derived from
umbilical cord mesenchymal stem cells. Acta Histochem. 2016;118:761–9.
41. El Omar R, Beroud J, Stoltz J-F, Menu P, Velot E, Decot V. Umbilical cord
mesenchymal stem cells: the new gold standard for mesenchymal stem
cell-based therapies? Tissue Eng Part B Rev. 2014;20:523–44.
42. Xu R, Greening DW, Zhu H-J, Takahashi N, Simpson RJ. Extracellular vesicle
isolation and characterization: toward clinical application. J Clin Invest. 2016;
126:1152–62.
43. Tomasoni S, Longaretti L, Rota C, Morigi M, Conti S, Gotti E, et al. Transfer of
growth factor receptor mRNA via exosomes unravels the regenerative effect
of mesenchymal stem cells. Stem Cells Dev. 2013;22:772–80.
44. Giebel B, Kordelas L, Börger V. Clinical potential of mesenchymal stem/
stromal cell-derived extracellular vesicles. Stem Cell Investig. 2017;4:84.
45. Aghajani Nargesi A, Lerman LO, Eirin A. Mesenchymal stem cell-derived
extracellular vesicles for kidney repair: current status and looming
challenges. Stem Cell Res Ther. 2017;8:273.
46. Grange C, Iampietro C, Bussolati B. Stem cell extracellular vesicles and
kidney injury. Stem Cell Investig. 2017;4:90.
Rota et al. Stem Cell Research & Therapy  (2018) 9:220 Page 14 of 14
